BioSpace News Archive

Increasing prevalence of cardiovascular diseases (CVDs) worldwide and rising demand for virtual cardiology solutions are some key factors expected to drive market revenue growth.

RVL Pharmaceuticals plc today announced that the Company will release its 2021 fourth quarter and full year financial results and provide an update of its first quarter 2022 Medical Aesthetic launch on Wednesday, March 30, 2022, after the close of the U.S. financial markets.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced the finalization of a strategic partnership with the Australian Federal Government to establish a state-of-the-art, domestic mRNA vaccine manufacturing facility in Australia.

Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617).

DUBAI, United Arab Emirates, According to the latest study by Future Market Insights, the Endoscopic Ultrasound Needles Market is expected to reach nearly US$ 223.5 million by 2025 end.

Albany NY, United States: Transparency Market Research has published a new report titled, “Medical Imaging Phantoms Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

DUBAI, United Arab Emirates, The In Vitro Diagnostics Market is indeed competitive, with numerous significant competitors.

Albany NY, United States: Transparency Market Research has published a new report titled, “Surgical Drills Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.According to the report, the global surgical drills market was valued at US $ 412.6 Mn in 2017.

Albany NY, United States: Viral clearance is the time that is taken by a virus to vanish from blood and not to be detected in blood tests.

Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2021.